Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles



Summary



GBI Research in its report “Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles” presents the use of endpoints or outcomes measures in respiratory disease’s clinical trials. In this report, endpoint used in asthma, cystic fibrosis, chronic obstructive pulmonary disorder and pulmonary arterial hypertension are presented. In this report detailed analysis about the clinical and surrogate endpoint used in various phases and stages of clinical trials are presented. This report presents detailed overview about the endpoint used in major marketed drugs and most promising molecules under development. The report contains company profiles of major companies involved with marketing of major marketed drugs under respiratory drug franchise.



Scope


- The report starts with an executive Summary, providing insights about the prominent endpoint used in respiratory clinical trials.
- This report deals with different types of endpoint used in respiratory clinical trials. It contains brief account of advantages, disadvantages and regulatory aspects of each type of endpoint.
- This report provides in-depth analysis of clinical trial endpoints used in asthma, COPD, cystic fibrosis and PAH clinical trials.
- This report covers complete account of primary and secondary endpoints used in Phase III and Phase II clinical trials in above mentioned respiratory diseases.
- In this report characterization and segmentation of trials based on their status, along with specific use of endpoints is also provided.
- This report provides profiling of major marketed drugs based on their safety, efficacy and clinical study details.
- The report contains company profiling of major companies associated with marketing of major respiratory drugs covering asthma, COPD, cystic fibrosis and PAH.
- This report also includes endpoint analysis of terminated trials for asthma, COPD, cystic fibrosis and PAH. Analysis of terminated trials can be used in designing more robust trials and avoid any issues, which can result in termination of trial.



Reasons to buy


- Understand the pattern of use of primary and secondary endpoints, according to specific indication’s and clinical Phase of trial. This will help in designing clinical trials so as to and protect one’s product from confronting any of the safety issues.
- To analyze the major primary and secondary endpoint used in disease specific clinical trials.
- Reinforce R&D strategies by identifying new endpoints to be used in disease and clinical phase specific clinical trials. This can increase positive outcome from a trial and aid in bringing molecules with increased efficiency and better safety profiles.
- Develop key strategic initiatives by understanding the key focus of major companies developing drugs in respiratory franchise.
- Build effective strategies by clinical phase wise endpoint analysis of clinical trials. This can help in reducing the drug’s time to market.
- Exploit strategies for designing of clinical trials by identifying the advantages and disadvantages involved with the use of specific endpoints.

Table Of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 13
3 Clinical Trials Endpoints in Respiratory Diseases - An Overview 14
3.1 Introduction 14
3.2 Types of Endpoints 14
3.2.1 Primary Endpoints 14
3.2.2 Secondary Endpoints 14
3.2.3 Surrogate Endpoints 15
4 Endpoints - Clinical Trials in Asthma - Marketed and Pipeline Products Assessment 16
4.1 Introduction 16
4.2 Primary Endpoints Used in Asthma Clinical Trials 20
4.2.1 Pulmonary Function Tests: 20
4.2.2 Vital Signs and Physical Activity 20
4.2.3 Biomarkers 20
4.2.4 Serious Adverse Events 20
4.3 Secondary Endpoints Used in Asthma Clinical Trials 21
4.3.1 Pharmacokinetics and Pharmacodynamics 21
4.3.2 Quality of Life Scores 21
4.3.3 Clinical Laboratory Tests - Biochemistry and Serum Hematology 21
4.3.4 Use of Rescue Medication 21
4.4 Asthma Therapeutics - Major Marketed Drugs 21
4.4.1 Singulair (Montekeulast Sodium) 21
4.4.2 Accolate Accoleit, Vanticon (Zafirlukast) 22
4.4.3 Zyflo (Zileuton) 23
4.4.4 Foradil (Formoterol Fumarate Inhalation Powder) 24
4.4.5 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) 25
4.4.6 Xolair (Omalizumab) 27
4.4.7 Serevent Diskus (Salmaterol Xinafoate Inhalation Powder) 28
4.4.8 Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder) 29
4.5 Asthma Therapeutics - Promising Drugs under Clinical Development 30
4.5.1 Daxas (Roflumilast) (Daxas, APTA 2217, B9302-107, BY 217, BYK 20869) 30
4.6 Phase III Clinical Trial Analysis 31
4.6.1 Completed Trial Analysis 31
4.6.2 Active Trial Analysis 35
4.6.3 Terminated Trial Analysis 39
4.7 Phase II Clinical Trial Analysis 41
4.7.1 Completed Trial Analysis 41
4.7.2 Active Trial Analysis 45
4.7.3 Terminated Trial Analysis 49
5 Endpoints - Clinical Trials in Chronic Obstructive Pulmonary Disorder - Marketed and Pipeline Products Assessment 76
5.1 Introduction 76
5.2 Primary Endpoints Used in COPD Clinical Trials 80
5.2.1 Pulmonary Function Tests 80
5.2.2 Baseline Dyspnea Index and Borg-Dyspnea Score 80
5.2.3 Rate of Exacerbations 80
5.2.4 Induced Sputum Analysis 80
5.2.5 Biomarkers of COPD 80
5.3 Secondary Endpoints Used in COPD Clinical Trials 80
5.3.1 Exercise Endurance Time 80
5.3.2 Serum Hematology 80
5.3.3 Six Minute Walk Distance 80
5.3.4 Time to First Exacerbation 81
5.4 COPD Therapeutics - Major Marketed Drugs 81
5.4.1 Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) 81
5.4.2 Brovana (Arformoterol) 82
5.4.3 Foradil Aerolizer (Formoterol Fumarate Inhalation Powder) 83
5.4.4 Symbicort (Budesonide/Formoterol Fumarate Dihydrate) 84
5.4.5 Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder) 85
5.4.6 Daxas (roflumilast) 87
5.5 COPD Therapeutics - Promising Drugs Under Clinical Development 88
5.5.1 Aclidinium Bromide 88
5.5.2 NVA237 (Glycopyrronium Bromide) 89
5.5.3 Dulera 89
5.6 Phase III Clinical Trial Analysis 90
5.6.1 Completed Trial Analysis 90
5.6.2 Active Trials Analysis 94
5.6.3 Terminated Trial Analysis 98
5.7 Phase II Clinical Trial Analysis 100
5.7.1 Completed Trial Analysis 100
5.7.2 Active Trial Analysis 104
5.7.3 Terminated Trial Analysis 107
6 Endpoints - Clinical Trials in Cystic Fibrosis - Marketed and Pipeline Products Assessment 125
6.1 Introduction 125
6.2 Primary Endpoints Used in Cystic Fibrosis Clinical Trials 129
6.2.1 Coefficient of Fat Absorption 129
6.2.2 Lung Microbiology 129
6.2.3 Biomarkers 129
6.3 Secondary Endpoints Used in Cystic Fibrosis Clinical Trials 129
6.3.1 Nasal Potential Difference 129
6.3.2 Sweat Chloride Concentration 129
6.4 Cystic Fibrosis Therapeutics - Major Marketed Drugs 129
6.4.1 Tobi (Tobramycin Inhalation Solution) 129
6.4.2 Pulmozyme (Dornase Alfa) 130
6.4.3 Cayston (aztreonam for Inhalation Solution) 131
6.4.4 Colistimethate sodium (Colistin, Colomycin Injection, Promixin, Coly-Mycin M) 132
6.5 Cystic Fibrosis - Promising Drugs Under Clinical Development 133
6.5.1 Denufosol Tetrasodium Inhalation Solution (INS37217) 133
6.5.2 VX-770 134
6.5.3 Bronchitol 134
6.5.4 Ataluren (PTC-124) 135
6.6 Phase III - Clinical Trial Analysis 136
6.6.1 Completed Trial Analysis 136
6.6.2 Active Trial Analysis 138
6.6.3 Terminated Trial Analysis 141
6.7 Phase II - Clinical Trial Analysis 143
6.7.1 Completed Trial Analysis 143
6.7.2 Active Trial Analysis 146
6.7.3 Terminated Trial Analysis 149
7 Endpoints - Clinical Trials in Pulmonary Arterial Hypertension - Marketed and Pipeline Products Assessment 156
7.1 Introduction 156
7.1.1 Classification of Pulmonary Hypertension 156
7.2 Primary Endpoints Used in Pulmonary Hypertension Trials 161
7.2.1 Cardiopulmonary Hemodynamic Test 161
7.2.2 Six Minutes Walking Distance 161
7.2.3 Biomarkers 161
7.3 Secondary Endpoints Used in Pulmonary Hypertension Trials 161
7.3.1 Time to Clinical Worsening 161
7.3.2 SF-36 Health Survey 161
7.4 Pulmonary Arterial Hypertension - Major Marketed Drugs 161
7.4.1 Tracleer 161
7.4.2 Remodulin 162
7.4.3 Revatio 163
7.4.4 Ventavis 164
7.4.5 Letairis 165
7.4.6 Adcirca 166
7.5 Pulmonary Arterial Hypertension - Promising Drugs under Clinical Development 167
7.5.1 ACT-064992 167
7.5.2 Oral Treprostinil 168
7.5.3 ACT-293987 168
7.5.4 Riociguat (BAY63-2521) 169
7.6 Phase III Clinical Trial Analysis 170
7.6.1 Completed Trial Analysis 170
7.6.2 Active Trial Analysis 172
7.6.3 Terminated Trial Analysis 175
7.7 Phase II Clinical Trial Analysis 177
7.7.1 Completed Trial Analysis 177
7.7.2 Active Trial Analysis 180
7.7.3 Terminated Trial Analysis 183
8 Endpoints - Clinical Trials in Respiratory Diseases - Company Profiling 187
8.1 GlaxoSmithKline Plc 187
8.1.1 Overview 187
8.1.2 Respiratory Disease Portfolio 187
8.2 AstraZeneca 188
8.2.1 Overview 188
8.2.2 Respiratory Disease Portfolio 188
8.3 F.Hoffmann La Roche 188
8.3.1 Overview 188
8.3.2 Respiratory Disease Portfolio 188
8.4 Merck and Co Inc 189
8.4.1 Overview 189
8.4.2 Respiratory Disease Portfolio 189
8.5 Novartis AG 189
8.5.1 Overview 189
8.5.2 Respiratory Disease Portfolio 190
8.6 Boehringer Ingelheim GmbH 190
8.6.1 Overview 190
8.6.2 Respiratory Disease Portfolio 190
9 Clinical Trials Endpoints in Respiratory Therapeutics - Appendix 191
9.1 Market Definitions 191
9.2 Abbreviations 191
9.3 Sources 192
9.4 Research Methodology 192
9.4.1 Clinical Trial Design Overview 192
9.4.2 Top Four Indications in Respiratory Therapy Area and their Product Profiling 193
9.4.3 Marketed and Pipeline Products Assessment 193
9.4.4 Company Profiling 193
9.4.5 Expert Panel Validation 194
9.5 Contact Us 194
9.6 Disclaimer 194

1.1 List of Tables

Table 1: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Distribution of Clinical Trials, By Company, 2000-2010 19
Table 2: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 32
Table 3: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 34
Table 4: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 36
Table 5: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 38
Table 6: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 39
Table 7: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 40
Table 8: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 42
Table 9: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 44
Table 10: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 46
Table 11: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 48
Table 12: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 49
Table 13: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 51
Table 14: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Phase III Clinical Trials, 2000-2010 52
Table 15: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Phase II Clinical Trials, 2000-2010 64
Table 16: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Distribution of Clinical Trials, By Company, 2000-2010 79
Table 17: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 91
Table 18: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 93
Table 19: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 95
Table 20: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 97
Table 21: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 98
Table 22: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 99
Table 23: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 101
Table 24: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 103
Table 25: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 104
Table 26: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 106
Table 27: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 107
Table 28: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 108
Table 29: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Phase III Clinical Trials, 2000-2010 109
Table 30: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Phase II Clinical Trials, 2000-2010 117
Table 31: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Distribution of Clinical Trials, By Company, 2000-2010 128
Table 32: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 136
Table 33: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2000-2010 137
Table 34: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 139
Table 35: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2000-2010 140
Table 36: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 141
Table 37: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2000-2010 142
Table 38: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 144
Table 39: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2000-2010 145
Table 40: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 147
Table 41: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2000-2010 148
Table 42: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 149
Table 43: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2000-2010 150
Table 44: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Phase III Clinical Trials, 2000-2010 151
Table 45: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Phase II Clinical Trials, 2000-2010 153
Table 46: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Distribution of Clinical Trials, By Company, 2002-2010 160
Table 47: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, 2002-2010 170
Table 48: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, 2002-2010 171
Table 49: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, 2002-2010 172
Table 50: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, 2002-2010 174
Table 51: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, 2002-2010 175
Table 52: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, 2002-2010 176
Table 53: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, 2002-2010 177
Table 54: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, 2002-2010 179
Table 55: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, 2002-2010 180
Table 56: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, 2002-2010 182
Table 57: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, 2002-2010 183
Table 58: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, 2002-2010 184
Table 59: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Phase III Clinical Trials, 2002-2010 185
Table 60: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Phase II Clinical Trials, 2002-2010 186
Table 61: GlaxoSmithKline Plc, Marketed Respiratory Drugs Portfolio, 2010 187
Table 62: AstraZeneca, Marketed Respiratory Drugs Portfolio, 2010 188
Table 63: F.Hoffmann La Roche, Marketed Respiratory Drugs Portfolio, 2010 188
Table 64: Merck and Co, Marketed Respiratory Drugs Portfolio, 2010 189
Table 65: Novartis AG, Marketed Respiratory Drugs Portfolio, 2010 190
Table 66: Boehringer Ingelheim, Marketed Respiratory Drugs Portfolio, 2010 190

1.2 List of Figures

Figure 1: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Total Number Of Clinical Trials, 2000-2010 16
Figure 2: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Phase of Clinical Trials, 2000-2010 17
Figure 3: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Status of Clinical Trials, 2000-2010 18
Figure 4: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Distribution of Clinical Trials, By Company (%), 2000-2010 19
Figure 5: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 31
Figure 6: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 33
Figure 7: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 35
Figure 8: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 37
Figure 9: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 39
Figure 10: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 40
Figure 11: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 41
Figure 12: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 43
Figure 13: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 45
Figure 14: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 47
Figure 15: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 49
Figure 16: Endpoints - Clinical Trials in Respiratory Disorders, Asthma, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 50
Figure 17: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Total Number of Clinical Trials, 2000-2010 76
Figure 18: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Phase of Clinical Trials, 2000-2010 77
Figure 19: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Status of Clinical Trials, 2000-2010 78
Figure 20: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Distribution of Clinical Trials, By Company (%), 2000-2010 79
Figure 21: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 90
Figure 22: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 92
Figure 23: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 94
Figure 24: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 96
Figure 25: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 98
Figure 26: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 99
Figure 27: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 100
Figure 28: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 102
Figure 29: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 104
Figure 30: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 105
Figure 31: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 107
Figure 32: Endpoints - Clinical Trials in Respiratory Disorders, COPD, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 108
Figure 33: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Total Number of Clinical Trials, 2000-2010 125
Figure 34: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Phase of Clinical Trials, 2000-2010 126
Figure 35: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Status of Clinical Trials, 2000-2010 127
Figure 36: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Distribution of Clinical Trials, By Company (%), 2000-2010 128
Figure 37: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 136
Figure 38: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2000-2010 137
Figure 39: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 138
Figure 40: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2000-2010 139
Figure 41: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 141
Figure 42: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2000-2010 142
Figure 43: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 143
Figure 44: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2000-2010 145
Figure 45: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 146
Figure 46: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2000-2010 148
Figure 47: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 149
Figure 48: Endpoints - Clinical Trials in Respiratory Disorders, Cystic Fibrosis, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2000-2010 150
Figure 49: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Total Number of Clinical Trials, 2002-2010 157
Figure 50: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Phase of Clinical Trials, 2002-2010 158
Figure 51: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Status of Clinical Trials, 2002-2010 159
Figure 52: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Distribution of Clinical Trials, By Company (%),2002-2010 160
Figure 53: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2002-2010 170
Figure 54: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase III Clinical Trials, (%), 2002-2010 171
Figure 55: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2002-2010 172
Figure 56: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase III Clinical Trials, (%), 2002-2010 173
Figure 57: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase III Clinical Trials, (%), 2002-2010 175
Figure 58: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase III Clinical Trials, (%),2002-2010 176
Figure 59: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2002-2010 177
Figure 60: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Completed Phase II Clinical Trials, (%), 2002-2010 178
Figure 61: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension Global, Primary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2002-2010 180
Figure 62: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Active Phase II Clinical Trials, (%), 2002-2010 181
Figure 63: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Primary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2002-2010 183
Figure 64: Endpoints - Clinical Trials in Respiratory Disorders, Pulmonary Arterial Hypertension, Global, Secondary Endpoint Analysis of Terminated Phase II Clinical Trials, (%), 2002-2010 184

Companies mentioned
GlaxoSmithKline Plc
AstraZeneca
F.Hoffmann La Roche
Merck and Co Inc
Novartis AG
Boehringer Ingelheim GmbH

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Enabling Technological Platforms for Lab-on-Chip Applications  (Technical Insights)

Enabling Technological Platforms for Lab-on-Chip Applications (Technical Insights)

  • $ 6 500
  • Industry report
  • June 2014
  • by Frost & Sullivan

6 Dimensional Assessment of Lab on a Chip Innovation Landscape A growing trend towards miniaturizing laboratory practices has been a major driving force behind the steady increase of innovations in the ...

Global Proteomics Market

Global Proteomics Market

  • $ 4 950
  • Industry report
  • May 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Proteomics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of ...

Label-Free Detection Market by Technology (Bio-layer interferometry, Optical waveguide grating technology, Surface Plasmon resonance), Consumables & Instruments, Applications (Lead Generation, Binding Kinetics), End user - Global Forecasts & Trends to 201

Label-Free Detection Market by Technology (Bio-layer interferometry, Optical waveguide grating technology, Surface Plasmon resonance), Consumables & Instruments, Applications (Lead Generation, Binding Kinetics), End user - Global Forecasts & Trends to 201

  • $ 4 650
  • Industry report
  • April 2014
  • by MarketsandMarkets

Label-free technology is rapidly gaining widespread acceptance as a drug discovery and life science research tool. Currently, the drug discovery process is based on target identification and screening ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.